BioMarin does another small deal to get early-stage bone disease asset
A week after ending development of a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very similar number. The California biopharma
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.